These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 37323705)

  • 1. Harnessing anti-tumor and tumor-tropism functions of macrophages via nanotechnology for tumor immunotherapy.
    Zheng Y; Han Y; Sun Q; Li Z
    Exploration (Beijing); 2022 Jun; 2(3):20210166. PubMed ID: 37323705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy.
    Liang C; Zhang Y; Wang S; Jiao W; Guo J; Zhang N; Liu X
    J Mater Chem B; 2024 May; 12(20):4809-4823. PubMed ID: 38695349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Macrophages for Cancer Immunotherapy and Drug Delivery.
    Xia Y; Rao L; Yao H; Wang Z; Ning P; Chen X
    Adv Mater; 2020 Oct; 32(40):e2002054. PubMed ID: 32856350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Macrophages for Tumor Therapy.
    Wang Y; Barrett A; Hu Q
    AAPS J; 2023 Aug; 25(5):80. PubMed ID: 37589825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 6. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-based cancer immunotherapy: Challenges and opportunities.
    Bai H; Feng L; Schmid F
    Exp Cell Res; 2024 Sep; 442(1):114198. PubMed ID: 39103071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage-modulating nanomedicine for cancer immunotherapy.
    Khan MM; Li Y; Zhou Z; Ni A; Saiding Q; Qin D; Tao W; Chen W
    Nanoscale; 2024 Apr; 16(15):7378-7386. PubMed ID: 38511468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomaterials-Involved Tumor-Associated Macrophages' Reprogramming for Antitumor Therapy.
    Li SL; Hou HY; Chu X; Zhu YY; Zhang YJ; Duan MD; Liu J; Liu Y
    ACS Nano; 2024 Mar; 18(11):7769-7795. PubMed ID: 38420949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomaterials targeting tumor associated macrophages for cancer immunotherapy.
    Zhao C; Pang X; Yang Z; Wang S; Deng H; Chen X
    J Control Release; 2022 Jan; 341():272-284. PubMed ID: 34813877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages.
    Zhang Y; Chen Y; Li J; Zhu X; Liu Y; Wang X; Wang H; Yao Y; Gao Y; Chen Z
    ACS Appl Mater Interfaces; 2021 Jun; 13(21):24442-24452. PubMed ID: 34008947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Associated Macrophages: A Potential Target for Cancer Therapy.
    Tan Y; Wang M; Zhang Y; Ge S; Zhong F; Xia G; Sun C
    Front Oncol; 2021; 11():693517. PubMed ID: 34178692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma.
    Liu Q; Huang W; Liang W; Ye Q
    Molecules; 2023 Feb; 28(5):. PubMed ID: 36903458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization.
    Shi L; Gu H
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor associated macrophages (TAMs) via nanocarriers.
    Singh Y; Pawar VK; Meher JG; Raval K; Kumar A; Shrivastava R; Bhadauria S; Chourasia MK
    J Control Release; 2017 May; 254():92-106. PubMed ID: 28377038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumor-associated macrophages for cancer immunotherapy.
    Cao X; Lai SWT; Chen S; Wang S; Feng M
    Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
    Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
    J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymersomes-Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1-Like Macrophage Repolarization.
    Rodriguez-Perdigon M; Jimaja S; Haeni L; Bruns N; Rothen-Rutishauser B; Rüegg C
    Macromol Biosci; 2022 Aug; 22(8):e2200168. PubMed ID: 35624036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
    Gao J; Liang Y; Wang L
    Front Immunol; 2022; 13():888713. PubMed ID: 35844605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.